ID   TSU-Pr1
AC   CVCL_4014
SY   Tsu-Pr1; TSU-PR1; TSUpr1; TSU
DR   BTO; BTO:0001065
DR   BioSample; SAMN03151952
DR   cancercelllines; CVCL_4014
DR   Cosmic; 704847
DR   Cosmic; 869158
DR   Cosmic; 921049
DR   Cosmic; 922552
DR   Cosmic; 923958
DR   Cosmic; 948073
DR   Cosmic; 1218867
DR   Cosmic; 2444243
DR   IARC_TP53; 753
DR   Wikidata; Q54973170
RX   CelloPub=CLPUB00698;
RX   PubMed=1873816;
RX   PubMed=3586177;
RX   PubMed=9018337;
RX   PubMed=10972993;
RX   PubMed=11304728;
RX   PubMed=11522622;
RX   PubMed=12725112;
RX   PubMed=16271951;
RX   PubMed=20143388;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a T24 derivative (PubMed=11304728; PubMed=11522622; PubMed=20143388; CelloPub=CLPUB00698). Originally thought to originate from a 73 year old male patient with a prostate carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00280.
CC   Population: Caucasian; Swedish.
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (PubMed=11304728; PubMed=11522622).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (PubMed=11304728; PubMed=11522622).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): PubMed=11304728; PubMed=11522622
ST   Amelogenin: X
ST   D13S317: 12
ST   D18S51: 16,18
ST   D21S11: 29
ST   D3S1358: 16
ST   D5S818: 10,12
ST   D7S820: 10,11
ST   D8S1179: 14
ST   FGA: 22
ST   vWA: 17
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0554 ! T24
SX   Female
AG   82Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 26
//
RX   CelloPub=CLPUB00698;
RA   van Bokhoven A.;
RT   "Models for prostate cancer. Molecular characterization and critical
RT   appraisal of human prostate carcinoma cell lines.";
RL   Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands.
//
RX   PubMed=1873816;
RA   Isaacs W.B., Carter B.S., Ewing C.M.;
RT   "Wild-type p53 suppresses growth of human prostate cancer cells
RT   containing mutant p53 alleles.";
RL   Cancer Res. 51:4716-4720(1991).
//
RX   PubMed=3586177; DOI=10.1016/S0022-5347(17)44488-0;
RA   Iizumi T., Yazaki T., Kanoh S., Kondo I., Koiso K.;
RT   "Establishment of a new prostatic carcinoma cell line (TSU-Pr1).";
RL   J. Urol. 137:1304-1306(1987).
//
RX   PubMed=9018337; DOI=10.1002/(SICI)1097-0045(19970101)30:1<58::AID-PROS9>3.0.CO;2-H;
RA   Webber M.M., Bello D., Quader S.T.A.;
RT   "Immortalized and tumorigenic adult human prostatic epithelial cell
RT   lines: characteristics and applications Part 2. Tumorigenic cell
RT   lines.";
RL   Prostate 30:58-64(1997).
//
RX   PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H;
RA   Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.;
RT   "Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon
RT   12 deletion variant in malignant human ovarian, prostate, and breast
RT   cancer cell lines.";
RL   Mol. Carcinog. 28:236-246(2000).
//
RX   PubMed=11304728; DOI=10.1002/pros.1045;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.;
RT   "Widely used prostate carcinoma cell lines share common origins.";
RL   Prostate 47:36-51(2001).
//
RX   PubMed=11522622;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Miller G.J.;
RT   "TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma
RT   cells and are not of prostatic origin.";
RL   Cancer Res. 61:6340-6344(2001).
//
RX   PubMed=12725112; DOI=10.1385/1-59259-372-0:21;
RA   Russell P.J., Kingsley E.A.;
RT   "Human prostate cancer cell lines.";
RL   Methods Mol. Med. 81:21-39(2003).
//
RX   PubMed=16271951; DOI=10.1016/j.cancergencyto.2005.04.010;
RA   Kim M.S., Kim S.H., Kim H.J., Hoang I.N., Oh W.M., Koh J.T.,
RA   Park H.O., Jeong J.Y., Kim W.J., Lee E.J., Koh J.Y., Kim B.Y.,
RA   Jensen R.H.;
RT   "Characterization of the TSU-PR1 cell line by chromosome painting and
RT   flow cytometry.";
RL   Cancer Genet. Cytogenet. 163:17-22(2005).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//